One dose of AstraZeneca’s COVID-19 vaccine (Vaxzevria) was 82% effective against hospitalization or death caused by either the Beta or Gamma variants of the SARS-CoV-2 virus, according to data from the Canadian Immunization Research Network, currently published as a pre-print.
Read More
Study: Ibrutinib Effective Treatment for Difficult to Treat Forms of Hairy Cell Leukemia
July 27th 2021The research team noted that although HCL has a good prognosis for the majority of patients, a small population will develop variants of the disease do not respond well to existing FDA-approved therapies or cannot tolerate the adverse effects of established therapies.
Read More
FDA Approves Expansion of Shingrix for Prevention of Herpes Zoster in Immunocompromised Adults
July 26th 2021Zoster vaccine recombinant, adjuvanted has been approved by the FDA for the prevention of herpes zoster in adults 18 years of age and older who are, or will be, at an increased risk of shingles because of immunodeficiency or immunosuppression.
Read More
Pharmacist Medication Insights: Phesgo for HER2-Positive Breast Cancer
July 26th 2021The combination of pertuzumab, trastuzumab and hyaluronidase–zzxf is indicated for adult patients with HER2-positive breast cancer that has spread to other parts of the body and for adult patients with early HER2-positive breast cancer.
Watch
Survey Finds 3 in 10 Americans Increased Supplement Use Since COVID-19 Pandemic
July 23rd 2021A new survey conducted by The Harris Poll on behalf of the Samueli Foundation found that 29% of Americans are taking more supplements compared with before the COVID-19 pandemic, bringing the nationwide percentage of supplement-takers to 76%.
Read More